Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.47 |
| ▸ | PLA2G2C | Q5R387 | 2/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | TLR2 | O60603 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9637036 | 0.87 | HSD17B10 (0.67) | MAPTHSD17B10USP2HTTSPHK1 | |
| SCHEMBL4865243 | 0.87 | HSD17B10 (0.67) | MAPTHSD17B10USP2HTTSPHK1 | |
| SCHEMBL7775489 | 0.87 | HSD17B10 (0.67) | MAPTHSD17B10USP2HTTSPHK1 | |
| SCHEMBL7671997 | 0.87 | HSD17B10 (0.67) | MAPTHSD17B10USP2HTTSPHK1 | |
| SCHEMBL7665310 | 0.87 | HSD17B10 (0.67) | MAPTHSD17B10USP2HTTSPHK1 | |
| SCHEMBL706278 | 0.87 | HSD17B10 (0.67) | MAPTHSD17B10USP2HTTSPHK1 | |
| SCHEMBL187049 | 0.87 | HSD17B10 (0.67) | MAPTHSD17B10USP2HTTSPHK1 | |
| SCHEMBL15070137 | 0.87 | HSD17B10 (0.67) | MAPTHSD17B10USP2HTTSPHK1 | |
| SCHEMBL21046009 | 0.87 | HSD17B10 (0.67) | MAPTHSD17B10USP2HTTSPHK1 | |
| SCHEMBL7661581 | 0.87 | HSD17B10 (0.67) | MAPTHSD17B10USP2HTTSPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024240858-A1 | PROTAC MOLECULES DIRECTED AGAINST DNA DAMAGE REPAIR SYSTEM AND USES THEREOF | VALERIO THERAPEUTICS (FR) | 2024-11-28 | — | — | WO | claimed |
| WO-2024240858-A1 | PROTAC MOLECULES DIRECTED AGAINST DNA DAMAGE REPAIR SYSTEM AND USES THEREOF | VALERIO THERAPEUTICS (FR) | 2024-11-28 | — | — | WO | disclosed |
| US-20230235327-A1 | A DBAIT MOLECULE IN COMBINATION WITH KRAS INHIBITOR FOR THE TREATMENT OF CANCER | VALERIO THERAPEUTICS (FR) | 2023-07-27 | — | — | US | disclosed |
| EP-4162045-A1 | A DBAIT MOLECULE IN COMBINATION WITH KRAS INHIBITOR FOR THE TREATMENT OF CANCER | ONXEO (FR) | 2023-04-12 | — | — | EP | disclosed |
| US-20220143049-A1 | A DBAIT MOLECULE IN COMBINATION WITH KINASE INHIBITOR FOR THE TREATMENT OF CANCER | VALERIO THERAPEUTICS (FR) | 2022-05-12 | — | — | US | disclosed |
| CN-114364798-A | Combination of Dbait molecules with kinase inhibitors for the treatment of cancer | 欧恩科斯欧公司 | 2022-04-15 | — | — | CN | disclosed |
| EP-3942045-A1 | A DBAIT MOLECULE IN COMBINATION WITH KINASE INHIBITOR FOR THE TREATMENT OF CANCER | ONXEO (FR) | 2022-01-26 | — | — | EP | disclosed |
| CN-108138177-B | The combination of Dbait molecule and PARP inhibitor is used for the purposes for the treatment of cancer | 法国居里学院 | 2019-03-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220143049-A1 | A DBAIT MOLECULE IN COMBINATION WITH KINASE INHIBITOR FOR THE TREATMENT OF CANCER | MAP3K20, MAP3K10, DCK | MAPT 3727/4885HSD17B10 3380/4885USP2 2740/4885 |
| US-20230235327-A1 | A DBAIT MOLECULE IN COMBINATION WITH KRAS INHIBITOR FOR THE TREATMENT OF CANCER | KRAS, TP53, NRAS | MAPT 4362/4885HSD17B10 3370/4885USP2 2521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.